Vaccine provides broad spectrum protection against the strains associated with coryza outbreaks in the U.S.
MADISON, N.J., Nov. 3, 2022 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it has reintroduced its Corvac-3 vaccine to help U.S. poultry producers combat outbreaks of avian coryza, an acute respiratory infection of chickens.
Corvac-3 provides broad-spectrum protection against disease caused by Avibacterium paragallinarum (coryza serotypes A, B or C) and is approved for use in chickens five weeks of age or older by subcutaneous injection. It has optimum antigen content and provides dependable development of immunity against the disease.
“In light of recent outbreaks of avian coryza, Merck Animal Health has relaunched its Corvac-3 vaccine in the U.S.” said Jim Stockam, D.V.M. for Merck Animal Health. “This vaccine is prepared from three inactivated strains of Avibacterium paragallinarum belonging to serotypes of A, B, and C and provides comprehensive protection against the strains associated with coryza outbreaks in the U.S.”
The product is now commercially available. It comes in a 500-ml (1,000 doses) presentation.
For more information about Corvac-3, contact your Merch Animal Health sales or technical services representative or visit https://www.merck-animal-health-usa.com/species/poultry/products/corvac-3.
CORVAC-3® PRODUCT LABEL: https://www.merck-animal-health-usa.com/offload-downloads/corvac-3-product-bulletin